Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein.

@article{Oerlemans2008MolecularBO,
  title={Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein.},
  author={Ruud Oerlemans and Niels E. F. Franke and Yehuda G Assaraf and Jacqueline Cloos and Ina van Zantwijk and Celia R Berkers and George L. Scheffer and Kabir Debipersad and Katharina Vojtekova and Clara Lemos and Joost W. van der Heijden and Bauke Ylstra and Godefridus J. Peters and Gertjan J L Kaspers and Ben A. C. Dijkmans and Rik J. Scheper and Gerrit Jansen},
  journal={Blood},
  year={2008},
  volume={112 6},
  pages={2489-99}
}
The proteasome inhibitor bortezomib is a novel anticancer drug that has shown promise in the treatment of refractory multiple myeloma. However, its clinical efficacy has been hampered by the emergence of drug-resistance phenomena, the molecular basis of which remains elusive. Toward this end, we here developed high levels (45- to 129-fold) of acquired resistance to bortezomib in human myelomonocytic THP1 cells by exposure to stepwise increasing (2.5-200 nM) concentrations of bortezomib. Study… CONTINUE READING
150 Citations
58 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 150 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 58 references

Amplification and mutation of PSMB5 gene in bortezomib resistant lymphoblastic leukemia cells derived from Jurkat line [abstract

  • S Lu, J Wang, J Yang
  • Blood
  • 2007

Molecular mechanisms of bortezomib resistance in acute lymphoblastic leukemia cells in comparison with multiple myeloma cells [abstract

  • NE Franke, R Oerlemans, S Zweegman
  • Blood
  • 2007

Similar Papers

Loading similar papers…